The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Fáber as a member of the Executive Board by five years to December 31, 2031. Dr. Fáber, who holds a Ph.D. in polymer chemistry from the Technical University of Munich, is responsible for the company's Bioprocess Solutions Division. He joined Sartorius as a scientist in 2002, held several management positions, and was appointed to the Executive Board in January 2019.
This leadership continuity is significant for the biopharmaceutical industry, where Sartorius serves as a leading international partner. The company's Bioprocess Solutions Division provides a broad portfolio of single-use solutions designed for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. Stability in executive leadership can be crucial for maintaining strategic direction and customer relationships in this highly specialized and regulated sector.
Sartorius's other major division, Lab Products & Services, focuses on innovative laboratory instruments and consumables for pharmaceutical, biopharmaceutical, and academic research laboratories. The company, based in Göttingen, Germany, has a strong global presence with approximately 60 production and sales locations worldwide. It employs more than 14,000 people and generated sales revenue of around 3.5 billion euros in 2025. The company regularly supplements its portfolio through acquisitions of complementary technologies.
The extension of Dr. Fáber's tenure provides stability as the company navigates its upcoming financial reporting calendar. Sartorius is scheduled to publish its first quarter results for January to March 2026 on April 23, 2026. This will be followed by the publication of half-year results on July 23, 2026, and nine-month results on October 22, 2026. For business and technology leaders, this executive decision signals confidence in the current leadership's ability to guide the company's growth in the competitive life sciences tools market, which is foundational to global healthcare innovation and drug development pipelines.
